Metrion Biosciences has launched a high-throughput NaV1.9 screening assay, offering laboratory managers a robust tool to expedite the development of non-opioid pain therapeutics. This assay addresses previous limitations in NaV1.9 research by providing a stable and reproducible platform for compound screening.
The assay's design incorporates a validated CHO cell line, optimized in-house for consistency and low variability. The inclusion of both human and rat-derived clones allows for comprehensive species selectivity studies, crucial for translational research.
By completing the NaV1.1–NaV1.9 assay suite, Metrion enables laboratories to conduct thorough selectivity profiling. The assay's compatibility with automated patch clamp systems, such as the Qube 384, supports high-throughput analysis, reducing project timelines and resource expenditure.
Benefits for Lab Managers:
- Operational Efficiency: High-throughput capabilities accelerate screening processes.
- Data Reliability: Optimized assay design ensures consistent and reproducible results.
- Resource Optimization: Integration with existing technologies minimizes additional infrastructure requirements.
- Comprehensive Analysis: Full sodium channel profiling supports informed decision-making in drug development.
- Cost-Effectiveness: Streamlined workflows contribute to reduced research and development costs.
This article has been sourced from a press release and may include content created or refined using AI tools and verified by our editorial team. For the full press release, visit: "Metrion Biosciences launches NaV1.9 high-throughput screening assay to strengthen screening portfolio and advance research on new medicines for pain."
